MEDIZINISCHE UNIVERSITÄT INNSBRUCK

29th Annual Conference
19–22 October 2022

ISOQOL 2022
Prague, Czech Republic

SISAQOL | IMI
Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints

In search of the holy grail of graphs

What do we know about visualization of group-level PRO data from cancer clinical trials for **health care professionals** and **other stakeholders**? Results from a systematic literature review

Lisa M. Wintner – Medical University of Innsbruck, Austria

SISAQOL-IMI

Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – Innovative Medicines Initiative

Recommendations on

- implementation of PRO measures in cancer clinical trial design,
- analysis of PRO data,
- harmonization of terms for clinically meaningful change and
- communication tools/visualisation of PRO data from clinical trials.

Disclaimer: The content of this presentation **MUST NOT** be taken as recommendations of the SISAQOL-IMI consortium.

Methods

2 step systematic search approach of online databases identifying

- studies/trials investigating visualisation formats of PRO data in oncology
- visualisation advice for PRO data irrespective of the medical field

title and abstract screening – full text screening – data extraction/synthesis

healthcare professionals (HCPs): mostly clinicians, nurses
other stakeholders: researchers, experts

Results

1,223 hits retrieved – 19 references included – 15 references provide information for HCPs; 7 for other stakeholders

Though there is no clear preference for a visualisation type across groups

- bar charts are valued for side-by-side comparisons (max. 6 bars/chart)
- pie charts are well understood and positively rated for proportions changed data
- icon arrays get mixed results, well understood but small differences are difficult to spot
- HCPs prefer to see data over time (line charts, max. 4 lines/chart)
- both groups favour annotations indicating statistical/clinical significance

Conclusions

There is no “one-size fits all” solution to be found in the literature.

Literature provides only few clear recommendations on the graphical presentation of group-level PRO data for HCPs and other stakeholders.

Different types of visualisations are needed depending on the study endpoint/used analysis.

SISAQOL-IMI will provide evidence- and consensus-based recommendations on how to communicate cancer clinical trial PRO data in different complexity levels.

Join for more visualisation content:
Friday Afternoon Poster Presentations
Slot 8

SISAQOL | IMI

Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints

Franziska Gross

Poster No. 2003

What do we know about visualisation of group-level PRO data from cancer clinical trials for **patients**?
Results from a systematic literature review

3:40 PM–3:55 PM Oct 21, 2022 (Europe - Prague)

ZENIT

This work is a group effort: Many thanks to

Franziska Gross[1]

Rosemary Peacock[2]

Florien Boele[2]

Jane Chang[4]

Galina Velikova[2]

Juan I. Arraras[3]

Bernhard Holzner[1]

all SISAQOL-IMI WP4 members

[1] Medical University of Innsbruck, Innsbruck, Austria; [2] University of Leeds, Leeds, United Kingdom; [3] Complejo Hospitalario de Navarra, Pamplona, Spain; [4] Pfizer Inc, New York, United States of America

Thank you very much for your attention!